Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-24-019505
Filing Date
2024-04-12
Accepted
2024-04-12 07:17:29
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20024347x2_defa14a.htm DEFA14A 11857
2 ny20024347x2_nc01.jpg GRAPHIC 497202
3 ny20024347x2_nc02.jpg GRAPHIC 329152
  Complete submission text file 0001140361-24-019505.txt   1150683
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40366 | Film No.: 24839968
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)